Investigational Antibody Treatment Shows Promise for Fibrotic Lung Diseases
Preclinical data reveals CAN10’s potential to target key proteins involved in systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
Tag: pulmonary fibrosis and IPF
All
Latest
All
Latest
Body’s Own Healing Mechanisms Could Reverse Lung Fibrosis
Researchers have identified a molecular pathway that leverages the body's natural healing processes to potentially reverse idiopathic pulmonary fibrosis.
All
Latest
Omega-3 Fatty Acids May Slow Pulmonary Fibrosis
Higher levels of omega-3 fatty acids were associated with better lung function and longer transplant-free survival in patients with pulmonary fibrosis, a new study finds.
FDA Greenlights Phase 2 Trial of OATD-01 for Pulmonary Sarcoidosis
The phase 2 clinical trial is expected to be a multi-center, randomized, double-blind, placebo-controlled study assessing the drug’s safety and effectiveness in treating approximately 90 pulmonary sarcoidosis patients.
Read More
Novel Imaging Agent Enables Early Detection of Pulmonary Fibrosis
A newly developed PET imaging agent can non-invasively identify pulmonary fibrosis in its early stages, reducing the need for unnecessary biopsies and allowing patients to begin treatment sooner.
Read More
Variant Cells Discovered in Lungs of IPF Patients
Stem cell cloning experts are reporting their findings of variant cells in the lungs of patients with idiopathic pulmonary fibrosis, which likely represent key targets in any future therapy for the condition.  Â
Read More
PFF Urges Patients to Use Only FDA-Approved Oxygen Devices
The medical advisory board of the Pulmonary Fibrosis Foundation issued a position statement on non-prescription supplemental oxygen.
Read More
Lung Care Provider Guide Available to Enhance Quality of Life for Lung Disease Patients
The new guide can assist providers in learning and practicing skills to prevent or manage respiratory symptoms in patients with chronic lung disease.
Read More
Biological Clock Contributes to Lung ScarringÂ
Researchers show how a biological clock molecule, called REV-ERBα, contributes to lung scarring, uncovering new potential drugs and drug targets along the way.
Read More
Pulmonary Fibrosis Strikes Black Patients a Decade Before Non-Black Patients
Black patients with pulmonary fibrosis are significantly younger than their Hispanic and white counterparts across a wide variety of disease metrics, including diagnosis, first hospitalization, lung transplant and death.
Read More
UIC Scientists Receive $13 Million to Study Lung Inflammation Mechanisms
The researchers hope the projects will lead to new avenues for treatments to help patients with conditions like COPD, pulmonary fibrosis, and acute respiratory distress syndrome.
Read More
Pilot Study Explores Early Detection of IPF Using X-Ray and AI
The study is investigating the possibility that X-ray imaging, when used with artificial intelligence, could facilitate earlier diagnosis and eventually more effective management of idiopathic pulmonary fibrosis.
Read More
aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read More
Toolkit to Support Clinicians in Quicker Diagnosis of ILDs
The new toolkit, shared on Rare Disease Day, aims to help clinicians shorten the time to diagnosis for pulmonary fibrosis and other interstitial lung diseases.
Read More
Patient & Caregiver Network Offers Aid to COPD, Asthma Patients
The American Lung Association has launched its Patient & Caregiver Network to support over 34 million Americans diagnosed with COPD, asthma, and other lung diseases.
Read More